SYRS - Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday March 27 2024

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, March 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.

To access the live conference call, please dial (888) 259-6580 (domestic) or (416) 764-8624 (international) and refer to conference ID 21905455. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com . An archived replay of the webcast will be available for approximately 30 days following the call.

About Syros Pharmaceuticals

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RAR? agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter ( @SyrosPharma ) and LinkedIn .

View source version on businesswire.com: https://www.businesswire.com/news/home/20240320845080/en/

Syros
Karen Hunady
Director of Corporate Communications & Investor Relations
1-857-327-7321
khunady@syros.com

Investors
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com